@article{4257ab2a919f4a40b753e67cc5d520e1,
title = "Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial",
author = "Kuo, \{Phillip H.\} and Taylor Benson and Richard Messmann and Michael Groaning",
note = "Funding Information: Phillip Kuo is an employee of Invicro. He is a consultant or speaker for Amgen, Eisai, Endocyte, GE Healthcare, Novartis, Invicro, Bayer, Chimerix, Fusion Pharma, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and GE Healthcare. Richard Messmann is an employee of Novartis and previously of Endocyte. Taylor Benson is an employee of Novartis and previously of Endocyte. Michael Groaning is an employee of Amgen and previously of Endocyte and Novartis. No other potential conflict of interest relevant to this article was reported.",
year = "2022",
month = jun,
day = "1",
doi = "10.2967/jnumed.121.263638",
language = "English (US)",
volume = "63",
pages = "816--818",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",
}